Dr. Anne Chiang on Molecular Testing in Lung Cancer Treatment Planning

Anne Chiang, MD, PhD
Published: Saturday, Nov 12, 2016



Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

There are currently 3 approved immunotherapy agents approved for lung cancer: pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq). If molecular testing shows a high level of PD-L1, patients are typically started on pembrolizumab, says Chiang.

However, not all patients across the country are being tested. Those who are not tested typically start treatment with nivolumab, when they could be seeing more benefit with pembrolizumab.

<<< View more from the 2016 New York Lung Cancer Symposium


Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses molecular testing in lung cancer and how it affects treatment decisions.

There are currently 3 approved immunotherapy agents approved for lung cancer: pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq). If molecular testing shows a high level of PD-L1, patients are typically started on pembrolizumab, says Chiang.

However, not all patients across the country are being tested. Those who are not tested typically start treatment with nivolumab, when they could be seeing more benefit with pembrolizumab.

<<< View more from the 2016 New York Lung Cancer Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x